Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794676 · ClinicalTrials.gov registry record
Genetic Evaluation of Families With Endocrine Cancers
A clinical trial of Pancreatic Cancer and Thymic Cancer, sponsored by Jersey Shore University Medical Center.
- Completed
- Registry status
- 9
- Enrollment target
- 1
- Study location
NCT01794676 is a study of Pancreatic Cancer and Thymic Cancer that has completed, run by Jersey Shore University Medical Center. The registered enrollment target is 9 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01794676, a study of Pancreatic Cancer and Thymic Cancer, has completed, sponsored by Jersey Shore University Medical Center.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to identify altered genetic factors that may exist and influence endocrine cancers in unrelated MEN1 families with different cancers. A grading system will be developed for endocrine cancers, including pancreatic cancers, thymus gland cancers, parathyroid disease and MEN1 syndrome as low-risk and high-risk to improve screening and timing of surgery.
Conditions Studied
Interventions
- GENETIC Blood draw
Study Locations (1)
New Jersey
- Jersey Shore University Medical Center - Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794676
The ClinicalTrials.gov registry entry for NCT01794676 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Jersey Shore University Medical Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT01794676 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01794676 about?
NCT01794676 is a clinical study titled "Genetic Evaluation of Families With Endocrine Cancers". This study is being conducted to identify altered genetic factors that may exist and influence endocrine cancers in unrelated MEN1 families with different cancers. A grading system will be developed for endocrine cancers, including pancreatic cancers, thymus gland cancers, parathyroid disease and ME...
What is the current status of trial NCT01794676?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2013-03. Estimated completion is 2015-10.
What conditions does trial NCT01794676 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Thymic Cancer, Parathyroid Disease, MEN1 Syndrome.
What interventions are being tested in trial NCT01794676?
The interventions under investigation include: Blood draw (GENETIC).
Who is sponsoring clinical trial NCT01794676?
This trial is sponsored by Jersey Shore University Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01794676 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.